In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory ...

Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission - including an outpatient dosing option using a single weight-based dose IND amendment ...

Independent Analysis Examines Photobiomodulation Format Differences, 660nm and 850nm Wavelength Science, and Consumer ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

Army Materiel Command brought together leaders from the Organic Industrial Base and the broader sustainment and acquisition ...

Universal Quantum has staked its reputation on the trapped-ion approach, allowing it to scale in the quickest and most ...

Facing deep financial and political challenges, the new mayor — a Latina former journalist — is betting New Orleans can still ...

Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...

William Blair welcomed the company’s update on its alignment with the U.S. FDA, saying it gives clear visibility into the ...

Elevated its score by two levels, advancing from a ‘B’ in FY 2023–24 to an ‘A’ in FY 2024–25 — placing ReNew among global leaders in climate disclosure Retains a strong ‘A-’ rating in CDP Water ...

Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...